U. S. SECURITIES AND EXCHANGE COMMISSION
                           Washington, D. C. 20549

                                FORM 10-QSB

(Mark One)
[X]   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                For the quarterly period ended March 31, 2001

[  ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

            For the transition period from ________ to ________

                       Commission File Number 0-31453

                               BILOGIC, INC.
      (Exact name of small business issuer as specified in its charter)


             Delaware                         23-3048627
         (State or other                   (I.R.S. Employer
         jurisdiction of                  Identification No.)
          incorporation)

                        3 Broad Street, Suite 300
                     Charleston, South Carolina 29401
                 (Address of principal executive offices)

                (Issuer's telephone number)(843) 534-1330

                              Not Applicable
            (Former name, former address and former fiscal year,
                       if changed since last report)

     Check whether the issuer  (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days.   Yes   X     No ____

                  APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date: as of May 10, 2001, the
Registrant had outstanding 11,000,000 shares of its Common Stock, $0.001
par value.


                                TABLE OF CONTENTS


                                                            Page

PART I  -  FINANCIAL INFORMATION

Item 1.  Financial Statements                                 3

     Balance Sheet                                            3
     Statement of Operations                                  4
     Statement of Cash Flows                                  5
     Notes to Financial Statements                            6

Item 2.  Management's Discussion and Analysis or
         Plan of Operation                                    8

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings                                    8
Item 2.  Changes in Securities and Use of Proceeds            8
Item 3.  Defaults on Senior Securities                        8
Item 4.  Submission of Matters to a Vote of Security
         Holders                                              8
Item 5.  Other Information                                    9
Item 6.  Exhibits and Reports on Form 8-K                     9

Signatures                                                    9

                                 -2-

PART I  - FINANCIAL INFORMATION
Item 1.     Financial Statements

BILOGIC, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
as at March 31, 2001
-----------------------

ASSETS:
-------

CURRENT ASSETS                                              $       0
                                                            ---------
      TOTAL CURRENT ASSETS                                          0
                                                            ---------
OTHER ASSETS                                                        0
                                                            ---------

 TOTAL ASSETS                                               $       0
                                                            =========

LIABILITIES and STOCKHOLDERS' EQUITY:
-------------------------------------

CURRENT LIABILITIES

Accounts Payable                                            $   2,000

 TOTAL LIABILITIES                                                  0
                                                            ---------

STOCKHOLDERS' EQUITY:
---------------------

   Preferred stock, $0.0001 par value;
   20,000,000 shares authorized, zero
   shares issued and outstanding                                    0

   Common stock, $0.0001 par value;
   100,000,000 shares authorized;
   11,000,000 shares issued and
   outstanding                                                  1,100

   Additional paid-in capital                                  19,400

   Accumulated deficit during
   development stage                                          (22,500)
                                                            ---------
       TOTAL STOCKHOLDERS' EQUITY                              (2,000)
                                                            ---------

 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                 $       0
                                                            =========
 The accompanying notes are an integral part of financial statements.

                                    -3-



BILOGIC, INC.
(A DEVELOPMENT STAGE COMPANY)

STATEMENT OF OPERATIONS
For the three months ended March 31, 2001
---------------------------------------------

INCOME                                                 $        0

Operating Expenses
      Consulting Fees                                      20,000
      Legal Fees                                            2,000

                                                       -----------

TOTAL EXPENSES                                             22,000
                                                       -----------

PROVISION FOR INCOME TAXES                                      0
                                                       -----------

NET LOSS                                                   22,000
                                                       ===========


NET LOSS PER COMMON SHARE                              $   (.003)
                                                       ===========

WEIGHTED AVERAGE NUMBER OF COMMON
 SHARES OUTSTANDING                                     7,066,667
                                                       ===========


 The accompanying notes are an integral part of financial statements.

                                   -4-


BILOGIC, INC.
(A DEVELOPMENT STAGE COMPANY)

STATEMENT OF CASH FLOWS
For the three months ended March 31, 2001
---------------------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES



Net Loss                                          (22,000)

Adjustment to reconcile net loss to net
cash provided by operations

    Increase (decrease) accounts payable            2,000


NET CASH USED IN OPERATING ACTIVITIES             (20,000)


CASH FLOWS FROM INVESTING ACTIVITIES
0
  Net Cash received from acquisition of
  Bilogic, Inc.                                    20,000


NET CASH PROVIDED BY INVESTING ACTIVITIES          20,000


CASH FLOWS FROM FINANCING ACTIVITIES                    0


NET INCREASE (DECREASE)                                 0


CASH, BEGINNING OF PERIOD                               0


CASH, END OF PERIOD                                     0


 The accompanying notes are an integral part of financial statements.

                                         -5-


BILOGIC, INC.
(A DEVELOPMENT STAGE COMPANY)

NOTES TO FINANCIAL STATEMENTS
As of March 31, 2001
-----------------------

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Organization and Business Operations

Bilogic, Inc., f/k/a Discovery Capital Funding Corp. (the "Company") was
incorporated in the State of Delaware on June 2, 2000 to serve as a vehicle
to effect a merger, exchange of capital stock, asset acquisition or other
business combination with a domestic or foreign private business. On March
1, 2001, the Company acquired all of the common stock of Bilogic, Inc., a
Delaware corporation, in consideration for 9,000,000 shares of common
stock.  On April 10, 2001, Bilogic, Inc. was merged with and into the
Company, and the Company changed its name to Bilogic, Inc.  Following the
acquisition of Bilogic, the Company's business is the development of an
internet-based application to reduce administrative inefficiencies in
medical patient records and billing.  The Company's ability to commence
operations is contingent upon its ability to raise the capital.

B. Use of Estimates

The preparation of the financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.

C. Cash and Cash Equivalents

For purposes of reporting the statement of cash flows, cash and cash
equivalents include highly liquid investments with maturities of three
months or less at the time of purchase.

D. Income Taxes

The Company accounts for income taxes under the Statement of Financial
Accounting Standards No. 109, "Accounting for Income Taxes," ("SFAS 109").
Under SFAS 109, deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax basis. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates
is recognized in income in the period that includes the enactment date.
There were no current or deferred income tax expense or benefits due to the
fact that the Company did not have any material operations for the period
from June 2, 2000 (inception) through March 31, 2001.

                                     -6-

BILOGIC, INC.
(A DEVELOPMENT STAGE COMPANY)

NOTES TO FINANCIAL STATEMENTS
As of March 31, 2001
-----------------------


NOTE 2.  STOCKHOLDERS' EQUITY

A. Preferred Stock

The Company is authorized to issue 20,000,000 shares of preferred stock at
$0.0001 par value, with such designations, voting and other rights and
preferences as may be determined from time to time by the Board of
Directors. The Company did not issue any shares of its preferred stock as
of March 31, 2001.

B. Common Stock

The Company is authorized to issue 100,000,000 shares of common stock at
$0.0001 par value. On June 2, 2000, the Company issued 5,000,000 shares of
its common stock to DotCom Internet Ventures Ltd. for an aggregate of $500
in services.  On March 1, 2001, DotCom Internet Ventures, Ltd. returned
3,000,000 shares of common stock for cancellation, and the Company issued
9,000,000 shares of common stock for the acquisition of Bilogic, Inc., a
Delaware corporation.

C. Warrant and Options

There are no warrants or options outstanding to issue any additional shares
of common stock.

NOTE 3  ACQUISITION OF BILOGIC, INC.

On March 1, 2001, the Company acquired 9,000,000 shares of Bilogic, Inc.
("Bilogic") by the issuance of 9,000,000 shares of its common stock to the
sole shareholder thereof.  Simultaneously, DotCom Internet Ventures Ltd.
returned 3,000,000 shares of common stock to the Company for cancellation.
At the time of the Company's acquisition of Bilogic, its sole assets
consisting of $20,000 cash.  Immediately following the acquisition, the
Company paid that cash to William Tay for consulting services to be
rendered by him in connection with the transition in ownership and
management of the Company.  Bilogic's business is the development of an
internet-based application to reduce administrative inefficiencies in
medical patient records and billing.

NOTE 4  MERGER OF BILOGIC, INC. INTO COMPANY AND NAME CHANGE

On April 10, 2001, the Company filed a Certificate of Resolution and Merger
to merge its wholly-owned subsidiary, Bilogic, Inc., with and into the
Company.  At the same time, the Company amended its Certificate of
Incorporation to change its name to Bilogic, Inc.

                                  -7-

Item 2.     Management's Discussion and Analysis or Plan of Operation.

Results of Operations for the Three Months ended March 31, 2001

During the three months ended March 31, 2001, the Company had no revenues
and incurred a net loss of $22,000.  The net loss was attributable to
consulting fees of $20,000 paid to a former principle of the Company for
services to be rendered in connection with the transition in ownership and
management of the Company, and $2,000 in legal expenses incurred by the
Company in connection with the Company's acquisition of BiLogic, Inc. on
March 1, 2001, and the Company's efforts to generate capital to fund its
business plan.

Following the acquisition of BiLogic, Inc. the Company's business is the
development of an internet-based application to reduce administrative
inefficiencies in medical patient records and billing.  The Company's
ability to commence operations is contingent upon its ability to raise
capital to fund its business plan.

Current management of the Company has spent considerable personal time and
resources, both before and since the Company's acquisition of BiLogic, Inc.
on March 1, 2001, in identifying the niche markets for the company,
conducting research to justify the market niche and developing the business
plan found in this Offering.  No expenses for such time or resources were
charged and/or accrued to the Company for these efforts.

Liquidity and Capital Resources

The Company does not have any current assets, and accounts payable of
$2,000.  The Company is currently in the process of raising capital to fund
its business plan.  In the event the Company is not successful in raising
such capital, it will never commence active operations.

PART II - OTHER INFORMATION

Item 1.     Legal Proceedings.

Not Applicable.

Item 2.     Changes in Securities and Use of Proceeds.

On March 1, 2001, the Company issued 9,000,000 shares of its common stock
to acquire all of the shares of common stock of Bilogic, Inc. from its sole
shareholder, Dr. Satish Shah.  The shares were issued pursuant to Section
4(2) of the Securities Act of 1933.

Item 3.     Defaults Upon Senior Securities.

Not applicable.

Item 4.     Submission of Matters to a Vote of Security Holders.

Not Applicable.

                                   -8-

Item 5.     Other Information.

On May 2, 2001, Bilogic, Inc. (the "Company" or "Bilogic") the Registrant
commenced a private offering of up to 3,500,000 shares of its common stock
at $1.00 per share (the "Offering").  The Offering is being conducted
pursuant to Rule 505 of Regulation D, promulgated under the Securities Act
of 1933.  The Company plans to offer the shares through its officers and
directors.  However, the Company may retain one or more broker/dealers to
sell shares in the Offering, and will pay any such participating
broker/dealers a commission of 10%.  At this time, the Company has not
retained any broker/dealers.  There is no minimum amount that must be sold,
and the proceeds of the Offering will be used as they are raised.  All
shares sold in the Offering will be restricted securities and will bear a
restrictive legend in accordance with Rules 144 and 502(d); however, the
Company has agreed as part of the Offering to file, within 30 days of the
completion of the Offering, a registration statement under the Securities
Act of 1933 to permit the resale of any shares sold in the Offering.

The Company is a development stage company that was formed to develop and
market a patient medical records system as an application service provider.

Item 6.     Exhibits and Reports on Form 8-K.

(a)  Exhibits.  Not Applicable.

(b)  Reports on Form 8-K.

The Company filed a Form 8-K dated March 1, 2001 reporting in Item 1 of a
change of control, in Item 2 of a material acquisition, in Item 6 of the
resignation of its sole officer and director, and in Item 7 that no
historical or pro forma financial statements were to be filed and including
a copy of the agreement to acquire Bilogic, Inc. as Exhibit 2.


                                 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                            BILOGIC, INC.

Date:  May 10, 2001         /s/ Dr. Satish Shah
                            By: Dr. Satish Shah
                            Its: Chairman of the Board and Chief
                                 Executive Officer